Phase 3b, Multicenter, Randomized, Controlled, Double-Blind Clinical Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines in Adults Aged 18 to 59 Years.
Latest Information Update: 26 May 2025
At a glance
- Drugs VLA 1553 (Primary) ; Dengue vaccine
- Indications Chikungunya virus infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 26 May 2025 New trial record